Contact us 24/7

Victoza

Victoza and Pancreatic Cancer

Thomas J. Henry is currently investigating reports of pancreatic cancer and other serious side effects linked to Novo Nordisk’s type 2 diabetes drug Victoza.

Approved by the U.S. Food and Drug Administration in 2010, Victoza (liraglutide) is part of a class of drug known as incretin mimetics.

In March 2013, the FDA released a statement warning patients and physicians of unpublished findings that link the class of diabetes medications to pre-cancerous cellular changes in the pancreas and pancreatic inflammation (pancreatitis).

Two drugs similar to Victoza, Byetta (exenatide) and Januvia (sitagliptin), have been the subject of multiple FDA warnings since 2007. Combined, the drugs have been linked to nearly 100 cases of acute pancreatitis, including both hemorrhagic and necrotizing pancreatitis, and at least two deaths.

The FDA is continuing its investigation into the link between Victoza and the development of pancreatic cancer.

ADVERSE EVENTS REPORTED WITH VICTOZA

  • Nausea
  • Vomiting
  • Abdominal pain
  • Fatigue
  • Acute Renal Failure
  • Acute Pancreatitis
  • Pancreatic Carcinoma
  • Death

HAVE YOU BEEN INJURED?

If you’ve been injured, we can help. Contact us